Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 516

1.

Optimal timing of salvage radiotherapy for biochemical recurrence after radical prostatectomy: is ultra-early salvage radiotherapy beneficial?

Taguchi S, Shiraishi K, Fukuhara H, Nakagawa K, Morikawa T, Naito A, Kakutani S, Takeshima Y, Miyazaki H, Nakagawa T, Fujimura T, Kume H, Homma Y.

Radiat Oncol. 2016 Jul 30;11:102. doi: 10.1186/s13014-016-0671-1.

2.

Different outcomes among favourable and unfavourable intermediate-risk prostate cancer patients treated with hypofractionated radiotherapy and androgen deprivation therapy.

Bracci S, Osti MF, Agolli L, Bertaccini L, De Sanctis V, Valeriani M.

Radiat Oncol. 2016 Jun 8;11:78. doi: 10.1186/s13014-016-0656-0.

3.

Biochemical recurrence-free survival and pathological outcomes after radical prostatectomy for high-risk prostate cancer.

Beauval JB, RoumiguiƩ M, Filleron T, Benoit T, de la Taille A, Malavaud B, Salomon L, SouliƩ M, Ploussard G.

BMC Urol. 2016 Jun 8;16(1):26. doi: 10.1186/s12894-016-0146-6.

4.

Lack of an Association between Neutrophil-to-Lymphocyte Ratio and PSA Failure of Prostate Cancer Patients Who Underwent Radical Prostatectomy.

Maeda Y, Kawahara T, Koizumi M, Ito H, Kumano Y, Ohtaka M, Kondo T, Mochizuki T, Hattori Y, Teranishi J, Yumura Y, Miyoshi Y, Yao M, Miyamoto H, Uemura H.

Biomed Res Int. 2016;2016:6197353. doi: 10.1155/2016/6197353.

5.

Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Localized and Advanced Prostate Cancer: A Systematic Review and Meta-Analysis.

Tang L, Li X, Wang B, Luo G, Gu L, Chen L, Liu K, Gao Y, Zhang X.

PLoS One. 2016 Apr 20;11(4):e0153981. doi: 10.1371/journal.pone.0153981. Review.

6.

MicroRNAs as Biomarkers for Diagnosis, Prognosis and Theranostics in Prostate Cancer.

Bertoli G, Cava C, Castiglioni I.

Int J Mol Sci. 2016 Mar 22;17(3):421. doi: 10.3390/ijms17030421. Review.

7.

Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy.

Yamashita S, Kohjimoto Y, Iguchi T, Koike H, Kusumoto H, Iba A, Kikkawa K, Kodama Y, Matsumura N, Hara I.

BMC Urol. 2016 Mar 22;16:13. doi: 10.1186/s12894-016-0133-y.

8.

Prostate Stem Cell Antigen Expression in Radical Prostatectomy Specimens Predicts Early Biochemical Recurrence in Patients with High Risk Prostate Cancer Receiving Neoadjuvant Hormonal Therapy.

Kim SH, Park WS, Kim SH, Park B, Joo J, Lee GK, Joung JY, Seo HK, Chung J, Lee KH.

PLoS One. 2016 Mar 16;11(3):e0151646. doi: 10.1371/journal.pone.0151646.

9.

Gene expression analysis of bone metastasis and circulating tumor cells from metastatic castrate-resistant prostate cancer patients.

Cho WJ, Oliveira DS, Najy AJ, Mainetti LE, Aoun HD, Cher ML, Heath E, Kim HR, Bonfil RD.

J Transl Med. 2016 Mar 15;14:72. doi: 10.1186/s12967-016-0829-5.

10.

Grading of prostatic adenocarcinoma: current state and prognostic implications.

Gordetsky J, Epstein J.

Diagn Pathol. 2016 Mar 9;11:25. doi: 10.1186/s13000-016-0478-2. Review.

11.

Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer.

Lindsay CR, Le Moulec S, Billiot F, Loriot Y, Ngo-Camus M, Vielh P, Fizazi K, Massard C, Farace F.

BMC Cancer. 2016 Feb 29;16:168. doi: 10.1186/s12885-016-2192-6.

12.

Beyond D'Amico risk classes for predicting recurrence after external beam radiotherapy for prostate cancer: the Candiolo classifier.

Gabriele D, Jereczek-Fossa BA, Krengli M, Garibaldi E, Tessa M, Moro G, Girelli G, Gabriele P; EUREKA-2 consortium..

Radiat Oncol. 2016 Feb 24;11:23. doi: 10.1186/s13014-016-0599-5.

13.

Genetic variants in ultraconserved regions associate with prostate cancer recurrence and survival.

Bao BY, Lin VC, Yu CC, Yin HL, Chang TY, Lu TL, Lee HZ, Pao JB, Huang CY, Huang SP.

Sci Rep. 2016 Feb 23;6:22124. doi: 10.1038/srep22124.

14.

Prognostic value of the bone scan index using a computer-aided diagnosis system for bone scans in hormone-naive prostate cancer patients with bone metastases.

Miyoshi Y, Yoneyama S, Kawahara T, Hattori Y, Teranishi J, Kondo K, Moriyama M, Takebayashi S, Yokomizo Y, Yao M, Uemura H, Noguchi K.

BMC Cancer. 2016 Feb 19;16:128. doi: 10.1186/s12885-016-2176-6.

15.

UHRF1 overexpression is involved in cell proliferation and biochemical recurrence in prostate cancer after radical prostatectomy.

Wan X, Yang S, Huang W, Wu D, Chen H, Wu M, Li J, Li T, Li Y.

J Exp Clin Cancer Res. 2016 Feb 17;35:34. doi: 10.1186/s13046-016-0308-0.

16.

Pretreatment neutrophil-to-lymphocyte ratio predicts the prognosis in patients with metastatic prostate cancer.

Kawahara T, Yokomizo Y, Ito Y, Ito H, Ishiguro H, Teranishi J, Makiyama K, Miyoshi Y, Miyamoto H, Yao M, Uemura H.

BMC Cancer. 2016 Feb 16;16:111. doi: 10.1186/s12885-016-2134-3.

17.

Prognostic value of a computer-aided diagnosis system involving bone scans among men treated with docetaxel for metastatic castration-resistant prostate cancer.

Uemura K, Miyoshi Y, Kawahara T, Yoneyama S, Hattori Y, Teranishi J, Kondo K, Moriyama M, Takebayashi S, Yokomizo Y, Yao M, Uemura H, Noguchi K.

BMC Cancer. 2016 Feb 16;16:109. doi: 10.1186/s12885-016-2160-1.

18.

Prognostic Value of Protocadherin10 (PCDH10) Methylation in Serum of Prostate Cancer Patients.

Deng QK, Lei YG, Lin YL, Ma JG, Li WP.

Med Sci Monit. 2016 Feb 16;22:516-21.

19.

Downregulation of miR-129 in peripheral blood mononuclear cells is a diagnostic and prognostic biomarker in prostate cancer.

Xu S, Yi XM, Zhou WQ, Cheng W, Ge JP, Zhang ZY.

Int J Clin Exp Pathol. 2015 Nov 1;8(11):14335-44.

20.

Prostate extracellular vesicles in patient plasma as a liquid biopsy platform for prostate cancer using nanoscale flow cytometry.

Biggs CN, Siddiqui KM, Al-Zahrani AA, Pardhan S, Brett SI, Guo QQ, Yang J, Wolf P, Power NE, Durfee PN, MacMillan CD, Townson JL, Brinker JC, Fleshner NE, Izawa JI, Chambers AF, Chin JL, Leong HS.

Oncotarget. 2016 Feb 23;7(8):8839-49. doi: 10.18632/oncotarget.6983.

Items per page

Supplemental Content

Loading ...
Support Center